The U.S. Supreme Court on Thursday left in place, for now, lower-court rulings that allow the mailing of the abortion pill mifepristone to continue while litigation proceeds. The order preserves the status quo in one of the most closely watched administrative-law and reproductive-rights disputes in the country, avoiding an immediate change to how patients and providers access medication abortion.

At a practical level, the Court’s action means that providers, pharmacies, and telehealth platforms may continue relying on the current federal framework that permits distribution by mail, rather than shifting abruptly to a more restrictive regime.

Litigation over mifepristone is poised to remain one of the most closely watched legal battlegrounds of 2026, with challenges unfolding across multiple fronts at once: federal agency authority, state abortion restrictions, drug distribution rules, and preemption.